Category: BioTech

BioTech

Biotech Most Volatile: Marina Biotech (OTCMKTS:MRNA), Onconova Therapeutics (NASDAQ:ONTX), OXiGENE Inc (NASDAQ:OXGN), Oragenics Inc (NYSEMKT:OGEN)

Marina Biotech, Inc. (OTCMKTS:MRNA) illustrated a similar run of events, as it reinvigorated its PR activity in the new year and shot upwards as it received a patent protection for one of its therapies. MRNA is back at $1.38, after it slumped for a while following a temporary peak at $1.70. Marina Biotech, Inc. (OTCMKTS:MRNA) stock performance was 16.67% in last session and finished the … Continue reading Biotech Most Volatile: Marina Biotech (OTCMKTS:MRNA), Onconova Therapeutics (NASDAQ:ONTX), OXiGENE Inc (NASDAQ:OXGN), Oragenics Inc (NYSEMKT:OGEN)

Chris Lewis
BioTech

Biotech Active Runners: Ariad Pharmaceuticals (NASDAQ:ARIA), Pfizer Inc. (NYSE:PFE), Gilead Sciences (NASDAQ:GILD), Novavax (NASDAQ:NVAX)

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) reported financial results for the fourth quarter and full year ended December 31, 2013 and provided an update on corporate developments. Net loss for the fourth quarter ended December 31, 2013 was $74.2 million, or $0.40 per share, compared to a net loss of $60.5 million, or $0.36 per share, for the same period in 2012. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) stock … Continue reading Biotech Active Runners: Ariad Pharmaceuticals (NASDAQ:ARIA), Pfizer Inc. (NYSE:PFE), Gilead Sciences (NASDAQ:GILD), Novavax (NASDAQ:NVAX)

Kristen Barton
BioTech

Biotech Unusual Volume: Northwest Biotherapeutics (NASDAQ:NWBO), La Jolla Pharmaceutical Company (NASDAQ:LJPC), OXiGENE (NASDAQ:OXGN), Tengion (OTCMKTS:TNGN)

Northwest Biotherapeutics Inc (NASDAQ:NWBO) a biotechnology company developing DCVax personalized immune therapies for solid tumour cancers, has received approval from the Paul Ehrlich Institute (PEI- the FDA of Germany) of a “Hospital Exemption” early access programme under Section 4b of the German Drug Law. Northwest Biotherapeutics, Inc (NASDAQ:NWBO) stock performance was 16.93% in last session and finished the day at $9.18. Traded volume was 8,391,894 … Continue reading Biotech Unusual Volume: Northwest Biotherapeutics (NASDAQ:NWBO), La Jolla Pharmaceutical Company (NASDAQ:LJPC), OXiGENE (NASDAQ:OXGN), Tengion (OTCMKTS:TNGN)

Mark DeFrance
BioTech

Biotech Losers: Aegerion Pharmaceuticals (NASDAQ:AEGR), Ocera Therapeutics (NASDAQ:OCRX), Onconova Therapeutics (NASDAQ:ONTX), CYANOTECH (NASDAQ:CYAN)

Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) was a big mover last session, as its shares rose nearly 11% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This reverses the trend for the healthcare company since Feb 24, as the stock is now down nearly 19%.stock performance was -7.00% in last session and finished the … Continue reading Biotech Losers: Aegerion Pharmaceuticals (NASDAQ:AEGR), Ocera Therapeutics (NASDAQ:OCRX), Onconova Therapeutics (NASDAQ:ONTX), CYANOTECH (NASDAQ:CYAN)

Colin Pettis
BioTech

Biotech Top Gainers: OXiGENE (NASDAQ:OXGN), AEterna Zentaris (NASDAQ:AEZS), Marina Biotech (OTCMKTS:MRNA), Dicerna Pharmaceuticals (NASDAQ:DRNA)

Shares of Oxigene Inc (NASDAQ:OXGN) more than doubled on very heavy volume after the microcap biotech said a mid-stage study of its drug Zybrestat, when used with Roche’s Avastin, showed increased survival in ovarian cancer patients. OXiGENE Inc (NASDAQ:OXGN) stock performance was 17.48% in last session and finished the day at $2.42. Traded volume was 6,334,713 million shares in the last session and the average … Continue reading Biotech Top Gainers: OXiGENE (NASDAQ:OXGN), AEterna Zentaris (NASDAQ:AEZS), Marina Biotech (OTCMKTS:MRNA), Dicerna Pharmaceuticals (NASDAQ:DRNA)

Jason Knox
BioTech, Stock Movers

BioTech in Focus: Myriad Genetics (NASDAQ:MYGN), Cantel Medical (NYSE:CMN), WuXi (NYSE:WX)

Myriad Genetics (NASDAQ:MYGN) is lower after the molecular diagnostic company disclosed in a regulatory filing Tuesday that the U.S. District Court for the District of Utah has denied the company’s motion for preliminary injunctive relief against Ambry Genetics’s sale of certain testing services that MYGN believes infringes on its patents. Shares are down 9.80% at $34.04, with a 52-week range of $20.02 – $39.15. Myriad … Continue reading BioTech in Focus: Myriad Genetics (NASDAQ:MYGN), Cantel Medical (NYSE:CMN), WuXi (NYSE:WX)

Richard Atkins